Multimodality Brain Imaging Markers in Progressive Supranuclear Palsy Subtypes and Parkinson's Disease

Area of Science:

• Neuroimaging
• Neurology
• Radiology

Background:

• The new classification of progressive supranuclear palsy (PSP) subtypes requires reliable radiological biomarkers for accurate clinical diagnosis.
• Distinguishing between PSP subtypes and Parkinson's disease (PD) is crucial for appropriate patient management.

Purpose of the Study:

• To evaluate the efficacy of various neuroimaging techniques in differentiating PSP subtypes from each other and from PD.
• To assess magnetic resonance imaging (MRI) morphometry, diffusion tensor imaging (DTI), susceptibility-weighted imaging (SWI), and [18F]fluorodeoxyglucose (^18FFDG)-positron emission tomography (PET) as diagnostic tools.

Main Methods:

• Quantitative analysis of MRI morphometry, including midbrain/pons area ratio and middle/superior cerebellar peduncle width ratio.
• Region of interest-based DTI, SWI, and ^18FFDG-PET analyses were performed on patients with PSP subtypes and PD.

Main Results:

• MRI morphometry and DTI successfully differentiated PSP-Richardson syndrome (PSP-RS) from other PSP subtypes and PD (AUC > 0.7).
• ^18FFDG-PET distinguished overall PSP from PD, but SWI did not differentiate among the studied groups.
• PSP-RS was identified as the subtype most distinguishable by MRI morphometry and DTI.

Conclusions:

• MRI morphometry and DTI are effective in differentiating PSP-RS from other common PSP subtypes and PD.
• These imaging modalities show potential as radiological markers for PSP-RS and warrant further investigation in larger cohorts.